Cure8 research brief
Links between circulating adaptive receptors, coordinated immune programs, and short-term treatment-response signals could eventually enable blood-based immune biomarkers or patient stratification tools in IBD research and clinical trials.
Researchers working on IBD immunology, biomarker development, and single-cell- or repertoire-based assays; clinicians interested in future immune-informed stratification; translational scientists planning validation studies.
This study used single-cell transcriptomics plus recovered TCR and BCR sequences from peripheral blood of 249 people (Crohn's disease, ulcerative colitis, and controls) to link receptor clonotypes and lineage maturation with coordinated T- and B-cell states.
Expanded T-cell clonotypes were associated with inflammatory-memory and cytotoxic programs; B-cell maturation (including class switching and somatic mutation) aligned with IgA-related mucosal and plasma B-cell programs.
The authors report covariance between T-cell programs (helper, regulatory, cytotoxic) and B-cell states and used repertoire-based machine learning to distinguish diagnosis, inflammation, and six-month treatment-response status.
This is an atlas-style, hypothesis-generating resource aimed at researchers; it does not provide clinical tests or validated biomarkers ready for patient care.
This is a bioRxiv preprint (not yet peer reviewed). The work is an observational atlas connecting repertoire features to transcriptional states and predictive models; reported distinctions and machine-learning findings require independent replication and clinical validation before they can inform patient care.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This paper explores whether polygenic risk scores (PRS) predict key long-term outcomes after IBD diagnosis — notably intestinal surgery — which could be relevant for risk stratification research and future clinical tools...
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.
